Specialty Pharmaceuticals
ELYNVORA
A specialty pharmaceuticals target portfolio built around high-need therapeutic areas — transplant immunology, neurology, oncology, and metabolic, cardio-renal and endocrine care.
Science you trust. For better health.
ELYNVORA is a specialty pharmaceuticals brand operating under the umbrella of ANADANI GROUP. It is developing a target portfolio of internationally sourced products with therapeutic value, through strategic partnerships with manufacturers. The target portfolio spans eleven molecules across transplant immunology, neurology, oncology and metabolic, cardio-renal and endocrine care — all oral solid forms, for professional use. Each product enters the final commercial portfolio only after manufacturing-site approval, completion of the quality and regulatory dossier, and registration or licensing in the importing country.
- 11 molecules
- 4 therapeutic areas
- Oral solid dose
- For professional use
About the brand
Reliable treatment options, sourced and supplied end to end.
Our mission
At ELYNVORA, we are committed to delivering high-quality pharmaceutical products through strategic partnerships with trusted manufacturers. Our mission is to provide reliable treatment options that address unmet medical needs and support better care for patients and partners across markets.
Our vision
To be a trusted specialty pharmaceuticals brand that bridges quality products, regulatory excellence, and operational reliability to deliver real value for our partners and the markets we serve.
Therapeutic areas
Four areas of high medical need.
ELYNVORA concentrates its portfolio where treatment options are specialised and reliability of supply matters most.
Transplant Immunology
Immunosuppressants used to prevent organ rejection after kidney, heart or liver transplantation, in combination with other therapies.
Neurology
Disease-modifying therapies for relapsing forms of multiple sclerosis, and antiepileptic treatment for partial-onset and generalized seizures.
Oncology
Targeted and cytotoxic therapies for prostate cancer, brain tumours, lung cancer and other solid tumours.
Metabolic, Cardio-Renal & Endocrine
Oral treatments for type 2 diabetes mellitus and related cardio-renal indications.
Target portfolio
Eleven molecules, four therapeutic areas.
ELYNVORA is developing a specialty portfolio of pharmaceutical products for its target markets. The addition of each product to the final commercial portfolio is subject to the selection and approval of the manufacturing site, the completion of the quality and regulatory dossier requirements, and obtaining the registration or licence required in the importing country before it is placed on the market.
For professional use only. Refer to the package insert before prescribing. The information on this page reproduces ELYNVORA’s product documentation for healthcare professionals and trade partners. It is not medical advice, and it is not an offer to supply in any market where a product is not authorised.
Transplant Immunology
2 products
Mycophenolate Mofetil
500 mg
Film-coated tablets
Therapeutic area
Transplant Immunology
Tacrolimus
0.5 mg / 1 mg / 5 mg
Capsules
Therapeutic area
Transplant Immunology
Neurology
3 products
Dimethyl Fumarate
240 mg
Delayed-release capsules
Therapeutic area
Neurology
Teriflunomide
14 mg
Film-coated tablets
Therapeutic area
Neurology
Levetiracetam
500 mg
Film-coated tablets
Therapeutic area
Neurology
Oncology
5 products
Enzalutamide
40 mg
Film-coated tablets
Therapeutic area
Oncology
Abiraterone Acetate
250 mg
Film-coated tablets
Therapeutic area
Oncology
Temozolomide
100 mg
Capsules
Therapeutic area
Oncology
Osimertinib
80 mg
Film-coated tablets
Therapeutic area
Oncology
Capecitabine
500 mg
Film-coated tablets
Therapeutic area
Oncology
Metabolic, Cardio-Renal & Endocrine
1 product
Empagliflozin
10 mg / 25 mg
Film-coated tablets
Therapeutic area
Metabolic, Cardio-Renal & Endocrine
Products, strengths, pack presentations and commercial availability may vary by market and according to the applicable registration requirements and regulatory approvals.
Product listings are limited to name, strength, dosage form and therapeutic area. Indications, clinical data and prescribing information are not published here — refer to the package insert. Product images show ELYNVORA’s own carton artwork.
How we work
One integrated model, from portfolio to market.
A fully integrated approach covering all key stages of product development and supply.
Portfolio development
Selecting molecules with real therapeutic value for the markets ELYNVORA serves.
Partner selection & sourcing
Building strategic partnerships with trusted manufacturers, and qualifying them before supply begins.
Regulatory compliance & quality assurance
Meeting the documentation and quality requirements of each destination market.
Supply chain management
Planning and controlling supply so committed volumes arrive when they are needed.
Distribution & market partnerships
Reaching healthcare systems through long-term distribution and market partners.
Quality commitment
Committed to quality. Dedicated to health.
Manufacturing site selection and approval
Selection and approval of the manufacturing site, completion of the quality and regulatory dossier requirements, and the registration or licence required in the importing country are completed before a product enters the final commercial portfolio.
Trusted by healthcare professionals worldwide
The molecules in this portfolio are established treatments, used by healthcare professionals internationally.
Marketing authorisation, manufacturing site and certification status are confirmed per product and per market on request. None is stated on this page, because none is stated in ELYNVORA’s own product documentation.
Our values
Five commitments, applied daily.
Quality
We are committed to the highest standards of quality, safety, and efficacy in everything we do.
Integrity
We build trust through transparency, honesty, and responsible business practices.
Innovation
We seek smarter solutions to address evolving healthcare needs and deliver better outcomes.
Partnership
We build long-term relationships based on trust, respect, and shared success.
Responsibility
We are committed to contributing to healthier societies and a more sustainable future.
Also from the group
The same standard, on the factory floor.
LUXSAFE is the group’s safety footwear brand, built to EN ISO 20345:2022. It is the other half of one idea: whether it is a medicine or a boot, what matters is that the documentation behind it holds up.
Let's build a lasting partnership.
Tell us what you need — a product specification, a quotation, a distribution agreement, or representation in a new market.
7, Grand-Rue, L-4132 Esch-sur-Alzette, Luxembourg